Braunstein Scott 的 Form 4 申報
Marinus Pharmaceuticals, Inc.（MRNS），2025/2/11 申報
- 申報編號
- 0001104659-25-011239
- 申報時間
- 2025/2/11
- 交易日
- 2024/8/14-2025/2/11
- 申報延遲
- 181 天遲報
- 10b5-1 計畫
- 沒有勾選
這份申報列了 3 筆非衍生性交易、9 筆衍生性交易。公開市場買進合計 $6,526.3。交易後 181 天才申報，超過 2 個營業日的期限。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Braunstein ScottCIK 0001643875 | 董事、高階主管（董事長、執行長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/2/11 | Common Stock | D交回公司處分 | −167,825 | $0.00 | $0 | 0 | 直接 | |
| 2025/2/11 | Common Stock | D交回公司處分 | −335,650 | $0.00 | $0 | 0 | 直接 | |
| 2025/2/11 | Common Stock | D交回公司處分 | −360,000 | $0.00 | $0 | 0 | 直接 | |
| 2025/2/11 | Common Stock | D交回公司處分 | −193,050 | $0.00 | $0 | 0 | 直接 | |
| 2025/2/11 | Common Stock | D交回公司處分 | −290,000 | $0.00 | $0 | 0 | 直接 | |
| 2025/2/11 | Common Stock | D交回公司處分 | −450,000 | $0.00 | $0 | 0 | 直接 | |
| 2025/2/11 | Common Stock | D交回公司處分 | −200,000 | $0.00 | $0 | 0 | 直接 | |
| 2025/2/11 | Common Stock | D交回公司處分 | −15,917 | $0.00 | $0 | 0 | 直接 | |
| 2025/2/11 | Common Stock | D交回公司處分 | −7,500 | $0.00 | $0 | 0 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.09 to $1.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F3
On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Common Stock held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash.
表 I 有 2 筆交易的價格引用這則附註。